Provided by Tiger Fintech (Singapore) Pte. Ltd.

Unity Biotechnology

0.7980
-0.0579-6.76%
Post-market: 0.7860-0.0120-1.50%17:58 EDT
Volume:168.40K
Turnover:136.80K
Market Cap:13.74M
PE:-0.49
High:0.8559
Open:0.8300
Low:0.7950
Close:0.8559
Loading ...

Unity Biotechnology reports Q1 EPS (43c), consensus (40c)

TIPRANKS
·
23 Apr

BRIEF-Unity Biotechnology Q1 Operating Income USD -6.891 Million

Reuters
·
23 Apr

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

GlobeNewswire
·
23 Apr

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

THOMSON REUTERS
·
23 Apr

UNITY Biotechnology Q1 Basic EPS USD -0.43

THOMSON REUTERS
·
23 Apr

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

Zacks
·
25 Mar

Positive Outlook for Unity Biotechnology Despite Initial Setback in UBX1325 Study

TIPRANKS
·
25 Mar

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires Live
·
25 Mar

Unity Biotechnology Shares Decline After Diabetic Edema Treatment Misses Primary Endpoint

MT Newswires Live
·
25 Mar

Unity Biotechnology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
24 Mar

HC Wainwright Adjusts Unity Biotechnology Price Target to $4 From $8, Maintains Buy Rating

MT Newswires Live
·
24 Mar

UNITY Biotechnology Inc : H.c. Wainwright Cuts Target Price to $4 From $8

THOMSON REUTERS
·
24 Mar

BUZZ-Unity Biotechnology falls as eye disease treatment fails in mid-stage trial

Reuters
·
24 Mar

Dow Jumps Over 300 Points; Chicago Fed National Activity Index Rises In February

Benzinga
·
24 Mar

UNITY Biotechnology Inc - Expects Complete 36-Week Data Results in Q2 2025

THOMSON REUTERS
·
24 Mar

UNITY Biotechnology Announces Topline Results From the Aspire Phase 2B Study in Diabetic Macular Edema

THOMSON REUTERS
·
24 Mar

UNITY Biotechnology Inc - Ubx1325 Shows Vision Gains Comparable to Aflibercept at Weeks 24 and 36

THOMSON REUTERS
·
24 Mar

UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

GlobeNewswire
·
24 Mar

UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

GlobeNewswire
·
24 Mar

BRIEF-UNITY Biotechnology appoints Yehia Hashad to its board

Reuters
·
10 Mar